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DRemote ischemic preconditioning for renal protection in children
undergoing surgery for complex congenital heart disease: What do we
know now and where do we go next?James S. Tweddell, MDIn 1986, Murry, Jennings, and Reimer1 found in a canine
model that brief periods of occlusion of the circumflex cor-
onary artery preceding a 40-minute period of ischemia fol-
lowed by reperfusion could reduce the size of the resultant
infarct. This phenomenon was termed ‘‘preconditioning.’’
Subsequent work found that this protective effect could be
elicited by creating brief ischemic episodes in tissue beds
remote from the organ to be rendered ischemic. The protec-
tive effect of these remote ischemic events could even occur
simultaneous to (percondititioning) or after (postcondition-
ing) the ischemic insult.2
Remote ischemic preconditioning (RIPC) has been
shown in 2 randomized controlled trials to improve cardiac
and pulmonary function in children undergoing cardiac
surgery.3,4 Other investigators have shown that RIPC hasa favorable impact on renal function.5 RIPC is an attractive
and exciting area of study. The technique unmasks an innate
ability to ameliorate ischemia–reperfusion (I-R) injury. No
drugs are required and the technique of RIPC appears to
have little or no potential for morbidity.
In the current study, the group from Aarhus University
Hospital, Skejby, Denmark, performed an extremely
well-structured randomized double-blind placebo-
controlled trial of RIPC to assess the potential for protec-
tion of renal function among children undergoing cardiac
surgery.6 On the basis of their initial hypothesis, they
found that RIPC provided no protection of renal function
in children operated on for complex congenital heart dis-
ease. Despite the ultimate clinical study design, perhaps
the optimal technique of RIPC for renal protection in
this patient population has not been identified. Do we
know enough about the proper timing, duration, type,
and quantity of vascular bed to be rendered temporarily
ischemic to merit a randomized trial? A subanalysis did
identify a benefit among patients greater than 6 months
of age, suggesting that there is an age-dependent response
to RIPC. Clearly, younger patients are at increased risk of
I-R injury and multiorgan dysfunction after operations us-
ing cardiopulmonary bypass. Any protective impact of
RIPC may have been overwhelmed by increased I-R injury
seen in young infants.rdiovascular Surgery c Volume 143, Number 3 583
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DThe authors of this study readily acknowledge its short-
comings. They had postulated an ambitious 30% reduction
in incidence of acute renal injury, whereas they observed
a more modest reduction of 10%. Using this 10% differ-
ence, they would have needed a much larger (n ¼ 480)
sample size. What next? Further study might look at
organ-specific preconditioning with age-specific ‘‘dose–
response curves’’ among the most susceptible groups. A
10% reduction in the incidence of acute renal injury could
be of clinical benefit, and a multicenter trial might accrue
enough patients within a realistic time frame to see whether
this reduction in acute renal injury would be realized. Like
all well-designed studies, this one by Pedersen and col-
leagues identifies areas of future study and adds signifi-
cantly to our understanding of RIPC.584 The Journal of Thoracic and Cardiovascular SurgReferences
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